Our data show that global pharma M&A is becoming more selective and strategically targeted. While North America remains the ...

Felix Gonzalez, FounderNest, offers a data-driven view of where pharma consolidation is occurring, where capital is being deployed, and how regional M&A strategies differ.

Next-generation biologics, such as bispecifics, fusion proteins, and multi-specifics, have multiple functionalities that ...

The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...

Digital GMP expectations are increasing, driven by Annex 11 and Annex 22, necessitating robust lifecycle management, data ...

Autonomy is not a binary option, Bryant said in the first part of this video interview with PharmTech ®, and can work in ...

In an expansion of his written three-part series for PharmTech, Jason Bryant of ArisGlobal explains the interplay between autonomy and accountability that is essential for AI agents assisting the ...

The year 2025 was defined by escalating global trade tensions that fundamentally reshaped the pharmaceutical supply chain, ...

In an expansion of his written three-part series for PharmTech, Jason Bryant of ArisGlobal explains the interplay between ...

FDA has taken steps to embrace AI in 2025, announcing in December that it will be providing agency staff with agentic AI ...

From a global regulatory perspective, Cytokinetics is expanding its footprint rapidly. The drug received approval in China on ...

Mike Stenberg, LGM Pharma, outlines how GLP-1s, AI, and 505(b)(2) delivery shifts are driving pharmaceutical innovation.